January 28th, 2011 - Volume 25 - Issue 3
pp: 279-397

Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals

Ho, Jason; Moir, Susan; Wang, Wei; More

AIDS. 25(3):295-302, January 28th, 2011.

Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children

Bunupuradah, Torsak; Kosalaraksa, Pope; Puthanakit, Thanyawee; More

AIDS. 25(3):315-323, January 28th, 2011.

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

Goodman, Derrick D; Zhou, Yun; Margot, Nicolas A; More

AIDS. 25(3):325-333, January 28th, 2011.

Concise Communications

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

Nelson, Mark; Stellbrink, Hans-Jürgen; Podzamczer, Daniel; More

AIDS. 25(3):335-340, January 28th, 2011.

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

Haïm-Boukobza, Stéphanie; Morand-Joubert, Laurence; Flandre, Philippe; More

AIDS. 25(3):341-344, January 28th, 2011.

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

Soliman, Elsayed Z; Lundgren, Jens D; Roediger, Mollie P; More

AIDS. 25(3):367-377, January 28th, 2011.

Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African–American elite controllers/suppressors

Salgado, Maria; Kirk, Gregory D; Cox, Andrea; More

AIDS. 25(3):385-387, January 28th, 2011.